Skip to content

BETAPLUS PHARMA

Active
Public limited companyfounded 2002active for 23 yearsHippokrateslaan 10, 1200 Sint-Lambrechts-Woluwe, Belgium97 active companies are registered at this addressKBO/BCE: BE 0479.037.369
Summary

BETAPLUS PHARMA has been active since 2002 and the Belgian Official Gazette contains no insolvency or warning signals. The 2025 annual accounts show equity of €22.3m and a net result of €1.3m. Equity is growing by about 7.6% per year across the filed financial years. Its solvency ranks better than 91% of 89 sector peers (NACE 21, financial year 2025). The computed 12-month bankruptcy probability is 0.1% (very low).

Financials · financial year 2025, full format

2025 annual accounts filed late (3 days) Filed on 3 August 2026, deadline 31 July 2026 (7 months after the close on 31 December 2025, Companies Code art. 3:10). Source: NBB, 2026-00373364.

Turnover
€5.4m▲ 0.3%
2024 · €5.4m
EBIT margin
23.2%▼ 2.4pp
2024 · 25.6%
Net result
€1.3m▼ 22.6%
2024 · €1.6m
Working capital
€23.1m▲ 5.6%
2024 · €21.8m
Trend over the years

2021 to 2025, 5 financial years 2018 to 2025, 8 financial years

The operating result falls in 2025; 2025 is 9% below 2024.

What the company sold each financial year and what was left of it. A loss stands below the zero line.

Turnover€5.4m 2025 Operating result€1.3m 2025 Net result€1.3m 2025

Use the arrow keys on the chart for the figures per year.

Sector: the middle half of NACE 21, Manufacture of basic pharmaceutical products and pharmaceutical preparations: a quarter of companies sit below it, a quarter above. Each year compared with accounts in the same format, and only where there are at least 30. Dashed line: the median. Available for Net result, Equity, Total assets, Working capital, Solvency, Current ratio, Return on assets (ROA), Staff (FTE).

Every figure with its change against the financial year before
favourable unfavourable
Line20182019202020212022202320242025
Turnover€6.0m-€6.1m▲ 0.6%€5.7m▼ 6.0%€6.1m▲ 7.0%€5.1m▼ 15.8%€4.5m▼ 11.4%€5.4m▲ 18.6%€5.4m▲ 0.3%
Operating result€2.5m-€2.0m▼ 22.5%€1.8m▼ 8.0%€2.2m▲ 24.4%€1.5m▼ 33.8%€0.6m▼ 56.5%€1.4m▲ 114%€1.3m▼ 9.3%
Net result€1.9m-€1.4m▼ 24.5%€1.4mwithin the sector's middle half▼ 1.1%€1.6mabove the sector's middle half▲ 14.4%€1.2mwithin the sector's middle half▼ 22.6%€1.0mwithin the sector's middle half▼ 21.3%€1.6mwithin the sector's middle half▲ 69.5%€1.3mwithin the sector's middle half▼ 22.6%
EBIT margin42.0%-32.4%▼ 9.6pp31.7%▼ 0.7pp36.8%▲ 5.2pp29.0%▼ 7.9pp14.2%▼ 14.7pp25.6%▲ 11.4pp23.2%▼ 2.4pp
Equity€12.8m-€14.2m▲ 11.0%€15.6mwithin the sector's middle half▲ 9.8%€17.2mwithin the sector's middle half▲ 10.2%€18.4mwithin the sector's middle half▲ 7.2%€19.4mwithin the sector's middle half▲ 5.3%€21.1mwithin the sector's middle half▲ 8.5%€22.3mwithin the sector's middle half▲ 6.0%
Total assets€15.5m-€16.8m▲ 8.5%€18.4mwithin the sector's middle half▲ 9.6%€19.9mwithin the sector's middle half▲ 8.0%€20.8mwithin the sector's middle half▲ 4.8%€21.9mwithin the sector's middle half▲ 5.1%€23.7mwithin the sector's middle half▲ 8.1%€24.9mwithin the sector's middle half▲ 5.1%
Debt€1.7m-€1.5m▼ 12.4%€1.6m▲ 6.3%€1.4m▼ 15.6%€0.9m▼ 30.2%€0.9m▼ 4.2%€1.0m▲ 14.4%€1.0m▼ 5.4%
Working capital€12.6m-€14.2m▲ 12.7%€15.8mabove the sector's middle half▲ 11.4%€17.6mabove the sector's middle half▲ 11.8%€19.0mabove the sector's middle half▲ 7.4%€20.2mabove the sector's middle half▲ 6.4%€21.8mabove the sector's middle half▲ 8.2%€23.1mabove the sector's middle half▲ 5.6%
Solvency82.8%-84.7%▲ 1.9pp84.9%above the sector's middle half▲ 0.2pp86.6%above the sector's middle half▲ 1.7pp88.6%above the sector's middle half▲ 2.0pp88.7%above the sector's middle half▲ 0.1pp89.0%above the sector's middle half▲ 0.3pp89.8%above the sector's middle half▲ 0.8pp
Current ratio8.31-10.39▲ 2.0910.84above the sector's middle half▲ 0.4514.05above the sector's middle half▲ 3.2021.07above the sector's middle half▲ 7.0223.29above the sector's middle half▲ 2.2222.08above the sector's middle half▼ 1.2124.55above the sector's middle half▲ 2.47
Return on assets (ROA)12.0%-8.4%▼ 3.7pp7.6%within the sector's middle half▼ 0.8pp8.0%within the sector's middle half▲ 0.5pp5.9%within the sector's middle half▼ 2.1pp4.4%within the sector's middle half▼ 1.5pp6.9%within the sector's middle half▲ 2.5pp5.1%within the sector's middle half▼ 1.8pp
Staff (FTE)10.5-11.1▲ 5.7%11.6below the sector's middle half▲ 4.5%12.5within the sector's middle half▲ 7.8%11.5below the sector's middle half▼ 8.0%11.5within the sector's middle half=11.5within the sector's middle half=11.3within the sector's middle half▼ 1.7%
above within below the middle half of NACE 21, Manufacture of basic pharmaceutical products and pharmaceutical preparations: a quarter of companies sit below it, a quarter above. Each year compared with accounts in the same format, and only where there are at least 30.
Balance-sheet composition
2025 in colour, 2024 as the grey bar beneath
Assets €24.9m
Fixed assets €835,211 ▲ 4.9%
Current assets €24.0m ▲ 5.1%
Equity and liabilities €24.9m
Equity €22.3m ▲ 6.0%
Provisions €1.6m =
Debt €978,856 ▼ 5.4%
Debt's share of the balance-sheet total falls from 4.4% to 3.9%. Equity is higher and debt is lower.
Key figures and ratios
2025 value · change against 2024
EBITDA
€1.5m▼
2024 · €1.6m
Cash flow
€1.5m▼
2024 · €1.8m
Quick ratio
24.22▲
2024 · 21.83
Debt to equity
0.04▼
2024 · 0.05
ROE
5.7%▼
2024 · 7.8%
Interest coverage
14.64▼
2024 · 17.55
Debt ≤ 1 year
€978,856▼
2024 · €1.0m
Income taxes
€458,608▼
2024 · €507,679
Staff costs
€1.2m▼
2024 · €1.2m
Green means a favourable move, even when the figure itself falls: as with debt or debt to equity.

Peer companies

Historical observation

Of the 20,139 companies that looked in July 2024 the way this one looks now, 0.2% went bankrupt within 24 months and 95.0% are still going.

  • Small
  • 20 years or older
  • solvency 30% or more
  • a profit of 5% of the balance sheet or more
0.2% went bankrupt
4.7% stopped otherwise
95.0% still going

For this company itself Checked computes a bankruptcy probability of 0.1% over twelve months; the group does not contradict it.

How reliable is this rule?

Tested on the year before, without using that year itself: the groups of July 2023 gave each of the 497,472 companies of July 2024 its group's bankruptcy share. Expected: 1.6%; actually bankrupt within 24 months: 1.7%.

The companies in ten equal groups, from lowest to highest expected share.
Group Expected Actual
1 0.2% 0.2%
2 0.3% 0.5%
3 0.5% 0.6%
4 0.7% 0.8%
5 0.9% 1.0%
6 1.3% 1.5%
7 1.6% 1.8%
8 1.8% 1.8%
9 3.0% 3.1%
10 5.6% 6.2%

The rule ranks well: a company that went bankrupt got a higher share than one that kept going in 74.5% of comparisons. The level follows the economy: in a year with more bankruptcies, the actual share is higher than the year before.

An observation about 20,139 comparable companies, not a prediction for this company. The sector does not count: the register keeps no sector for companies that stopped, so it would make the outcome look better than it was.

Annual accounts
Filed annual accounts As filed with the NBB · 2025 against 2024 · 58 lines
Balance sheet Code20242025
Assets
Total assets20/58€23.7m€24.9m▲
Fixed assets21/28€0.8m€0.8m▲
Intangible fixed assets21€0€0.02m▲
Tangible fixed assets22/27€0.8m€0.8m▲
Land and buildings22€0.06m€0.1m▲
Plant, machinery and equipment23€0.6m€0.6m▲
Furniture and vehicles24€0.04m€0.02m▼
Leasing and similar rights25-€0.003m
Assets under construction and advance payments27€0.07m€0.05m▼
Financial fixed assets28€0.05m€0.04m▼
Current assets29/58€22.9m€24.0m▲
Stocks and contracts in progress3€0.3m€0.3m▲
Stocks30/36€0.3m€0.3m▲
Amounts receivable within one year40/41€22.5m€23.7m▲
Trade receivables40€0.6m€0.6m▼
Other amounts receivable41€21.9m€23.1m▲
Cash at bank and in hand54/58€0.002m€0.01m▲
Deferred charges and accrued income490/1€0.1m€0.02m▼
Equity and liabilities
Total equity and liabilities10/49€23.7m€24.9m▲
Equity10/15€21.1m€22.3m▲
Contributions10/11€2.4m€2.4m=
Capital10€2.0m€2.0m=
Issued capital100€2.0m€2.0m=
Contributions outside capital11€0.4m€0.4m=
Share premium1100/10€0.4m€0.4m=
Reserves13€0.2m€0.2m=
Non-distributable reserves130/1€0.2m€0.2m=
Legal reserve130€0.2m€0.2m=
Profit (loss) carried forward14€18.5m€19.7m▲
Provisions and deferred taxes16€1.6m€1.6m=
Provisions for liabilities and charges160/5€1.6m€1.6m=
Environmental obligations163€1.6m€1.6m=
Amounts payable17/49€1.0m€1.0m▼
Amounts payable within one year42/48€1.0m€1.0m▼
Trade debts44€0.7m€0.8m▲
Suppliers440/4€0.7m€0.8m▲
Taxes, remuneration and social security45€0.4m€0.2m▼
Taxes450/3€0.05m-
Remuneration and social security454/9€0.3m€0.2m▼
Income statement Code20242025
Turnover70€5.4m€5.4m▲
Goods, raw materials, services and sundry goods60/61€2.5m€2.7m▲
Remuneration, social security and pensions62€1.2m€1.2m▼
Depreciation of and write-downs on formation expenses, intangible and tangible fixed assets630€0.2m€0.2m▲
Write-downs on stocks, contracts in progress and trade receivables: additions (reversals)631/4€445-€0.002m▼
Other operating charges640/8€0.02m€0.02m▼
Gross operating margin9900€2.8m€2.7m▼
Operating profit (loss)9901€1.4m€1.3m▼
Financial income75/76B€0.9m€0.6m▼
Recurring financial income75€0.9m€0.6m▼
Financial charges65/66B€0.09m€0.1m▲
Recurring financial charges65€0.09m€0.1m▲
Profit (loss) for the period before taxes9903€2.2m€1.7m▼
Income taxes67/77€0.5m€0.5m▼
Profit (loss) for the period9904€1.6m€1.3m▼
Profit (loss) for the period to be appropriated9905€1.6m€1.3m▼
Appropriation of the result
Profit (loss) to be appropriated9906€18.5m€19.7m▲
Profit (loss) brought forward from the previous period14P€16.8m€18.5m▲
Social balance sheet
Average headcount (FTE)908711.511.3▼

The notes to these accounts (10 items: statements of assets and debts, cost breakdowns, rights and commitments) are not shown here.

Line20182019202020212022202320242025Change
Turnover70€6.0m€6.1m€5.7m€6.1m€5.1m€4.5m€5.4m€5.4m▲ 0.3%
Goods, raw materials, services and sundry goods60/61---€2.2m€2.2m€2.3m€2.5m€2.7m▲ 6.0%
Remuneration, social security and pensions62---€1.2m€1.1m€1.2m€1.2m€1.2m▼ 1.4%
Depreciation of and write-downs on formation expenses, intangible and tangible fixed assets630€0.3m€0.3m€0.3m€0.3m€0.2m€0.2m€0.2m€0.2m▲ 6.0%
Write-downs on stocks, contracts in progress and trade receivables: additions (reversals)631/4----€221-€0.001m€0.001m€445-€0.002m-
Provisions for liabilities and charges: additions (uses and reversals)635/8---€0.1m€0.1m€0.1m---
Other operating charges640/8---€0.01m€0.01m€0.02m€0.02m€0.02m▼ 2.1%
Gross operating margin9900-€3.3m€3.3m€3.9m€3.0m€2.2m€2.8m€2.7m▼ 4.8%
Operating profit (loss)9901€2.5m€2.0m€1.8m€2.2m€1.5m€0.6m€1.4m€1.3m▼ 9.3%
Financial income75/76B---€0.05m€0.2m€0.7m€0.9m€0.6m▼ 32.9%
Recurring financial income75€0.08m€0.07m€0.06m€0.05m€0.2m€0.7m€0.9m€0.6m▼ 32.9%
Financial charges65/66B---€0.003m€0.009m€0.03m€0.09m€0.1m▲ 11.1%
Recurring financial charges65€0.02m€0.02m€0.005m€0.003m€0.009m€0.03m€0.09m€0.1m▲ 11.1%
Debt charges650€0.001m--------
Profit (loss) for the period before taxes9903€2.7m€2.0m€1.9m€2.3m€1.6m€1.4m€2.2m€1.7m▼ 19.6%
Income taxes67/77€0.8m€0.6m€0.5m€0.7m€0.4m€0.4m€0.5m€0.5m▼ 9.7%
Profit (loss) for the period9904€1.9m€1.4m€1.4m€1.6m€1.2m€1.0m€1.6m€1.3m▼ 22.6%
Profit (loss) for the period to be appropriated9905€1.9m€1.4m€1.4m€1.6m€1.2m€1.0m€1.6m€1.3m▼ 22.6%
Line20182019202020212022202320242025Change
Assets
Total assets20/58€15.5m€16.8m€18.4m€19.9m€20.8m€21.9m€23.7m€24.9m▲ 5.1%
Fixed assets21/28€1.2m€1.1m€1.0m€0.9m€0.9m€0.8m€0.8m€0.8m▲ 4.9%
Intangible fixed assets21-€0--€0.03m€0€0€0.02m-
Tangible fixed assets22/27€1.1m€1.1m€1.0m€0.8m€0.9m€0.8m€0.8m€0.8m▲ 2.2%
Land and buildings22---€0.03m€0.03m€0.04m€0.06m€0.1m▲ 59.8%
Plant, machinery and equipment23---€0.5m€0.6m€0.7m€0.6m€0.6m▲ 3.3%
Furniture and vehicles24---€0.1m€0.07m€0.05m€0.04m€0.02m▼ 46.0%
Leasing and similar rights25-------€0.003m-
Assets under construction and advance payments27---€0.1m€0.1m€0€0.07m€0.05m▼ 30.3%
Financial fixed assets28€0.05m€0.03m€0.04m€0.04m€0.03m€0.03m€0.05m€0.04m▼ 4.9%
Current assets29/58€14.3m€15.7m€17.4m€19.0m€19.9m€21.1m€22.9m€24.0m▲ 5.1%
Stocks and contracts in progress3€0.2m€0.2m€0.2m€0.2m€0.3m€0.3m€0.3m€0.3m▲ 24.4%
Stocks30/36---€0.2m€0.3m€0.3m€0.3m€0.3m▲ 24.4%
Amounts receivable within one year40/41€14.0m€15.3m€17.0m€18.5m€19.5m€20.7m€22.5m€23.7m▲ 5.3%
Trade receivables40---€0.5m€0.4m€0.3m€0.6m€0.6m▼ 4.2%
Other amounts receivable41---€18.0m€19.1m€20.4m€21.9m€23.1m▲ 5.6%
Cash at bank and in hand54/58€0.03m€0.03m€0.06m€0.2m€0.04m€0.01m€0.002m€0.01m▲ 491%
Deferred charges and accrued income490/1---€0.05m€0.04m€0.04m€0.1m€0.02m▼ 83.7%
Equity and liabilities
Total equity and liabilities10/49€15.5m€16.8m€18.4m€19.9m€20.8m€21.9m€23.7m€24.9m▲ 5.1%
Equity10/15€12.8m€14.2m€15.6m€17.2m€18.4m€19.4m€21.1m€22.3m▲ 6.0%
Contributions10/11€2.0m€2.0m€2.0m€2.4m€2.4m€2.4m€2.4m€2.4m=
Capital10---€2.0m€2.0m€2.0m€2.0m€2.0m=
Issued capital100---€2.0m€2.0m€2.0m€2.0m€2.0m=
Contributions outside capital11---€0.4m€0.4m€0.4m€0.4m€0.4m=
Share premium1100/10---€0.4m€0.4m€0.4m€0.4m€0.4m=
Reserves13€0.2m€0.2m€0.2m€0.2m€0.2m€0.2m€0.2m€0.2m=
Non-distributable reserves130/1---€0.2m€0.2m€0.2m€0.2m€0.2m=
Legal reserve130---€0.2m€0.2m€0.2m€0.2m€0.2m=
Profit (loss) carried forward14€10.2m€11.6m€13.0m€14.6m€15.9m€16.8m€18.5m€19.7m▲ 6.9%
Provisions and deferred taxes16€0.9m€1.1m€1.2m€1.3m€1.4m€1.6m€1.6m€1.6m=
Provisions for liabilities and charges160/5---€1.3m€1.4m€1.6m€1.6m€1.6m=
Environmental obligations163---€1.3m€1.4m€1.6m€1.6m€1.6m=
Amounts payable17/49€1.7m€1.5m€1.6m€1.4m€0.9m€0.9m€1.0m€1.0m▼ 5.4%
Amounts payable within one year42/48€1.7m€1.5m€1.6m€1.4m€0.9m€0.9m€1.0m€1.0m▼ 5.4%
Trade debts44€0.8m€1.1m€1.2m€0.9m€0.5m€0.6m€0.7m€0.8m▲ 14.9%
Suppliers440/4---€0.9m€0.5m€0.6m€0.7m€0.8m▲ 14.9%
Taxes, remuneration and social security45---€0.4m€0.4m€0.3m€0.4m€0.2m▼ 44.3%
Taxes450/3---€0.3m€0.2m€0.1m€0.05m--
Remuneration and social security454/9---€0.2m€0.2m€0.2m€0.3m€0.2m▼ 36.0%
Line20182019202020212022202320242025Change
Profit (loss) for the period9904€1.9m€1.4m€1.4m€1.6m€1.2m€1.0m€1.6m€1.3m▼ 22.6%
+ Depreciation and write-downs630€0.3m€0.3m€0.3m€0.3m€0.2m€0.2m€0.2m€0.2m▲ 6.0%
Operating cash flow (approximation)€2.1m€1.7m€1.7m€1.9m€1.4m€1.2m€1.8m€1.5m▼ 19.4%
Investment in fixed assets (approximation)--€0.2m-€0.2m-€0.2m-€0.3m-€0.1m-€0.2m-€0.3m▼ 33.6%
Change in cash-€202€0.03m€0.2m-€0.2m-€0.03m-€0.009m€0.01m-

Simplified and derived: a Belgian filing has no cash-flow statement, so these rows come from the income statement and the balance-sheet moves.

Download as CSV

Latest 10 of 23 filings with the National Bank
Financial year Type Filed Reference
31-12-2025 full format 03-08-2026 2026-00373364
31-12-2024 full format 16-07-2025 2025-00288402
31-12-2023 full format 02-07-2024 2024-00222313
31-12-2022 full format 21-08-2023 2023-00380305
31-12-2021 full format 15-11-2022 2022-20519894
25-12-2020 full format 10-06-2021 2021-19800017
31-12-2019 full format 04-08-2020 2020-39600306
31-12-2018 full format 06-08-2019 2019-44800188
31-12-2017 full format 23-08-2018 2018-49200408
31-12-2016 full format 24-08-2017 2017-50800426

Show all 23 filings

Similar companies · same sector, comparable size

Of the 147 active companies whose main activity is manufacture of basic pharmaceutical products and pharmaceutical preparations (NACE 21100), figures are known for 108. 24 are within a factor 10 of this equity. These 5 are the closest to it. See the whole sector

Public contracts

3 awards · 2024 to 2025
Raamovereenkomst voor aankoop van 18F FDG voor PET Scan
buyer: AZ Sint-Jan Brugge AVMedical equipment and pharmaceuticalsawarded 16-12-2025€1.5m2 tendersTED 17176-2026
CHL: fourniture de [18F]fluorodéoxyglucose.: FDG.
buyer: Centre Hospitalier de Luxembourg (CHL)Medical equipment and pharmaceuticalsawarded 14-10-2024€607,0001 tenderTED 708841-2025
18F-FDG VOOR HET PET/CT CENTRUM
buyer: Vzw AZ Sint-Lucas & VolkskliniekPetroleum products, fuel and electricityawarded 20-08-2024€1.4m2 tendersTED 518279-2024

Source: TED (Tenders Electronic Daily), Publications Office of the European Union. Values as the buyer published them; for a framework agreement, a ceiling.